Adjuvant interferon-a (IFN-a) therapy is used to control certain types of cancer in clinics. For hepatocellular carcinoma (HCC), IFN-a therapy is effective in only a subgroup of patients; therefore, identifying biomarkers to predict the response to IFN-a therapy is of high significance and clinical utility. As the induced IFN-stimulated gene expression following IFN-a treatment plays pivotal roles in IFN-a effects, we screened IFN-stimulated gene expression in HCC tissues and found that several IFN-stimulated genes were significantly decreased in HCC. Interestingly, expression of IFN-induced protein with tetratricopeptide repeats (IFIT) family members, including IFIT1, IFIT2, IFIT3, and IFIT5, was decreased in HCC tissues. We further analyzed the expression of IFIT family members in HCC and their roles in patients' responses to IFN-a therapy in two independent randomized controlled IFN-a therapy clinical trials of HCC patients. We found that higher expression of IFIT3, but not other IFITs, in HCC tissues predicts better response to IFN-a therapy, suggesting that IFIT3 may be a useful predictor of the response to IFN-a therapy in HCC patients. Mechanistically, IFIT3 enhanced the antitumor effects of IFN-a by promoting IFN-a effector responses both in vitro and in vivo. IFIT3 could bind signal transducer and activator of transcription 1 (STAT1) and STAT2 to enhance STAT1-STAT2 heterodimerization and nuclear translocation upon IFN-a treatment, thus promoting IFN-a effector signaling. Conclusion: Higher IFIT3 expression in HCC tissues predicts better response to IFN-a therapy in HCC patients; IFIT3 promotes IFN-a effector responses and therapeutic effects by strengthening IFN-a effector signaling in HCC. (HEPATOLOGY 2017;66:152-166) 
I
mmunotherapy has advanced to the forefront of advanced cancer treatment in recent years. Immune checkpoint blockade, T-cell adoptive transfer, together with administration of known cytokine therapy such as interferon-a (IFN-a) have been verified in the clinic to induce durable therapeutic responses in certain cancer patients. (1) (2) (3) (4) However, only a subgroup of patients respond to these immunotherapies, and there is a great need for identifying reliable biomarkers to predict the individual cancer patients most likely to respond to the immunotherapy. (5, 6) For example, it has been recently shown that a higher tumor mutation burden enriches for responsiveness to cytotoxic T lymphocyte antigen 4 blockade therapy in patients with melanoma and to programmed cell death protein 1 inhibition in those with non-small cell lung cancer and mismatch repair-deficient colorectal cancer. (7) (8) (9) Currently, much attention has been paid to the screening and identification of biomarkers for Abbreviations: AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; IFIT, IFN-induced protein with tetratricopeptide repeats; IFN-a, interferon-a; ISG, IFN-stimulated gene; siRNA, small interfering RNA; STAT1, signal transducer and activator of transcription 1; TMA, tissue microarray. the responsiveness to cancer immunotherapy, and the investigation is still an ongoing process. (10) Hepatocellular carcinoma (HCC) is prevalent worldwide and currently is the second leading cause of cancer-related mortality. (11) Only 30%-40% of HCC patients are amenable to curative resection or transplantation, owing partially to the late appearance of symptoms. (12) Currently, molecular target therapy, such as sorafenib, somewhat increases the overall survival of patients with advanced disease (13) ; however, the therapeutic efficacy needs to be improved. Now, chronic inflammation, immunosuppressive microenvironment, and T-cell exhaustion are all demonstrated to contribute to the carcinogenesis and progression of HCC. (14) Thus, immunotherapy becomes an attractive approach to HCC treatment. Looking back to the history of HCC therapy, IFN has been studied extensively in HCC patients as an adjuvant therapy in the advanced setting and at a variety of doses, schedules, and combinations over the last decade. IFN-a has been determined to have clinical benefit in prolonging overall survival of HCC patients, but its clinical use is limited due to the high reported toxicity and the difficulties in identifying those who respond well. (15) (16) (17) (18) Nevertheless, IFN-a therapy has been suggested to be effective in a subgroup of HCC patients. HCC patients with single-nodule tumor who have undergone ablation therapy, with low microRNA-26a expression or with high retinoic acid-inducible gene I expression in tumor tissues, have been shown to have better responses to adjuvant IFN-a therapy. (19) (20) (21) More interestingly, the IFN and innate immune signaling pathway have emerged as intriguing determinants of immunotherapy response and resistance. (22) Combination approaches have been explored to engage IFN signaling so as to boost innate immune activation. For example, anti-cluster of differentiation 20 antibody coupled with IFN-a had a better antitumor effect than anti-cluster of differentiation 20 antibody alone in the treatment of lymphoma. (23) Clearly, a detailed understanding of the IFN signaling pathway is valuable to improve the combination immunotherapy and the immunotherapy of HCC.
IFN-a downstream effector signaling includes activation of the Janus kinase-signal transducer and activator of transcription (STAT) signaling cascade and the induction of downstream transcription of IFNstimulated genes (ISGs). Activation of STAT1 and STAT2, which are phosphorylated by upstream Janus kinases, form heterodimers, translocate into nucleus, and initiate the transcription of ISGs upon IFN treatment, plays pivotal roles in IFN effector signaling. (24) (25) (26) Induced ISGs are responsible for the diverse biological functions of IFN-a. Also, ISGs can positively or negatively regulate IFN effector signaling in a feedback manner. (21, 27, 28) Currently, the functions of ISGs in the regulation of infection and cancer, especially their roles in modulating IFN effector signaling and responses to IFN-a therapy, have attracted much attention but are still not well understood.
In order to elucidate the roles of ISGs in modulating responses to IFN-a therapy in HCC patients, we previously screened the expression of ISGs in HCC tissues and found that expression of retinoic acidinducible gene I was decreased in HCC tissue. And retinoic acid-inducible gene I bears considerable potential as a biomarker for the prediction of responses to IFN-a therapy in HCC patients. (21) 
Materials and Methods

CLINICAL SPECIMENS
Three cohorts of HCC patients were enrolled in this study. Cohort 1 included 358 patients from Zhongshan Hospital (Shanghai, China); cohort 2 included 76 HCC patients from the University of Hong Kong (Hong Kong, China); cohort 3 included 75 HCC patients from Zhongshan Hospital. Cohorts 2 and 3 were from two independent clinical trials of adjuvant IFN-a therapy for HCC patients. Cohort 2 included 39 HCC patients in the control group and 37 in the IFN-a treatment group, which was a subset of patients, as reported (16) ; cohort 3 included 35 HCC patients in the control group and 40 in the IFN-a treatment group, which was also a subset of patients, as reported. (15) All patients in cohorts 2 and 3 first underwent radical resection of HCC, then were randomly assigned to the control and IFN-a-treated groups, respectively; and both groups were strictly followed as described. (15, 16) The resected tumor tissue was then prepared as tissue microarray (TMA) slides. (21) Normal human liver tissues were obtained from distal normal liver tissues of 20 liver hemangioma patients. All samples were collected with written informed consent from the patients and approved by the institutional review board at each study center.
REAGENTS
Antibodies specific to phospho-STAT1 (9171), STAT1 (9172), b-actin (4970), Lamin A/C (2032), and horseradish peroxidase-coupled secondary antibodies (7074 and 7076) were from Cell Signaling Technology (Danvers, MA). Antibody specific to Flag-tag (F1804) was from Sigma (St. Louis, MO). Antibodies specific to phospho-STAT2 (ab53132), STAT2 (ab124283 and ab106094), IFIT3 (ab76818 and ab191689), hepatocyte antigen (ab75677), and V5-tag (ab9116) were from Abcam (Cambridge, MA). Cholesterol-conjugated IFIT3 small interfering RNA (siRNA) for in vivo RNA interference and its negative control were from Ribobio Co. (Guangzhou, China). (29) CELL LINES AND TRANSFECTION HCC cell lines BEL-7402 and SMMC-7721 were obtained and cultured as described. (21) IFIT3-knockout BEL-7402 cells were prepared by the CRISPR/Cas9 approach. Cells (5 3 10 4 or 2 3 10 5 ) were seeded into each well of 24-well or 6-well plates, respectively; incubated overnight; and then transfected with RNAs using INTERFERin (Polyplus-transfection, France), as described. (29, 30) TMA AND IMMUNOHISTOCHEMISTRY IFIT3 expression in tissues was determined using TMA. TMAs were assembled as described. (21) Briefly, the different samples were punched out from selected regions of tissues and assembled into a new paraffin block. TMAs were sectioned (5 lm) and stained with hematoxylin and eosin to verify histology. Immunohistochemical staining was performed on 5-lm sections. The primary anti-IFIT3 antibody (ab76818; Abcam) was diluted 1:200 in phosphate-buffered saline containing 1% bovine serum albumin and incubated at 4 8C overnight. On the next day, immunostaining was performed using the Dako ChemMate EnVision Detection Kit Peroxidase/Diaminobenzidine Rabbit/ Mouse (Dako, Glostrup, Denmark). Pictures were acquired using the HistoFAXS system, and mean staining intensity was calculated using Histoquest software (both from TissueGnostics, Vienna, Austria), which represents the quantitative protein expression level of IFIT3.
IN VIVO ASSAY
All animal experiments were undertaken in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals, with the approval of the Scientific Investigation Board of the Second Military Medical University (Shanghai, China). The human HCC-bearing nude mouse model (SMMC-LTNM) was prepared by transplanting histologically intact fresh human HCC tissues to form subcutaneous transplantation tumor in nude mice and then continuously maintained with subcutaneous passage. (29) For delivery of cholesterol-conjugated RNA, 10 nmol RNA in 0.1 mL saline buffer was locally injected into the tumor mass once every 3 days. (29) Recombinant IFN-a-2b (5 3 10 6 U/kg; Kaiyinyisheng, Beijing, China) was injected subcutaneously daily. (21) Tumor size was measured and serum alphafetoprotein (AFP) was detected as described. (29) RNA ISOLATION AND REAL-TIME QUANTITATIVE RT-PCR ANALYSIS Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. Real-time quantitative RT-PCR analysis was performed using LightCycler (Roche, Switzerland) and the SYBR RT-PCR kit (Takara, Dalian, China) with primers as reported. (21) The relative expression level of the individual genes was normalized to that of internal control b-actin using the 2 -DDCt cycle threshold method in each sample.
RNA INTERFERENCE
Human IFIT3-specific siRNA 1 was 5 0 -GCU AUG GAC UAU UCG AAU ATT-3 0 (sense) and 5 0 -UAU UCG AAU CCA UAG CTT-3 0 (antisense); human IFIT3-specific siRNA 2 was 5 0 -GGC AAG CUG AAG AGU UAA UTT-3 0 (sense) and 5 0 -AUU AAC UCU UCA GCU UGC CTT-3 0 (antisense); scrambled control RNA was 5 0 -UUC UCC GAA CGU GUC ACG UTT-3 0 (sense) and 5 0 -ACG UGA CAC GUU CGG AGA ATT-3 0 (antisense). siRNA was synthesized by GenePharma (Shanghai, China). siRNA duplexes were transfected at a final concentration of 10 nM.
APOPTOSIS ASSAY
At 48 hours posttransfection, cells were stimulated with 1,000 U/mL human IFN-a-2b for the indicated time, then harvested, washed, resuspended in the staining buffer, and examined with the Annexin V-FITC Apoptosis Detection Kit (Calbiochem, Darmstadt, Germany). Stained cells were examined by flow cytometry using FACSCalibur, and data were analyzed with Cell Quest software (both from Becton Dickinson, Mountain View, CA). Annexin V-positive cells were regarded as apoptotic cells. (29) 
IMMUNOPRECIPITATION AND WESTERN BLOT
Cells or tissues were harvested and lysed with M-PER Protein Extraction Reagent (Pierce, Rockford, IL) supplemented with protease inhibitor cocktail (Calbiochem). Nuclear protein was extracted using NE-PER nuclear and Cytoplasmic Extraction Reagents (Pierce). Protein concentrations of the extracts were measured with the bicinchoninic acid assay (Pierce) and equalized with the extraction reagent. An equal amount of the extracts was used for immunoprecipitation or loaded and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes, and then blotted as described. (31) 
STATISTICAL ANALYSIS
Data are shown as mean 6 standard error of the mean or presented directly. Statistical comparisons between experimental groups were analyzed by unpaired Student t test, and a two-tailed P < 0.05 was taken to indicate statistical significance. For analyzing the clinical variables in the HCC cohorts, the chi-squared test and one-way analysis of variance were used, with the P values indicated. Kaplan-Meier survival analysis was used to compare HCC patient survival based on dichotomized IFIT3 expression with statistical P values generated by the log-rank test. Cox proportional hazards regression analyses were used to analyze the effect of clinical variables on patient survival. A univariate test was used to examine the influence of each clinical variable on survival. A multivariate analysis was performed considering clinical variables from the univariate analysis that were significantly associated with survival, with significance set at P < 0.05. P values and hazard ratios are shown. All statistical analyses were performed using SPSS 17.0 (Chicago, IL).
Results
EXPRESSION OF IFIT FAMILY MEMBERS IS DECREASED IN HCC TISSUES
We obtained paraffin-embedded HCC tissues and paired liver tissues from 509 HCC patients who had undergone radical resection between 1999 and 2011. This study involved three independent cohorts of HCC patients. Expression of IFIT1, IFIT2, IFIT3, and IFIT5 in HCC tissues and surrounding liver tissues of the 358 patients in cohort 1 was analyzed using immunohistochemistry. Cohorts 2 and 3 included 76 and 75 HCC patients, respectively, and were from two independent, prospective, randomized, controlled trials of adjuvant IFN-a therapy for HCC patients. (15, 16, 21) In cohorts 2 and 3, expression of IFIT3 was determined and the correlation between IFIT3 expression and IFN-a therapeutic response evaluated.
Most of the HCC patients in the three cohorts were men (83.3%) and carriers of hepatitis B virus (HBV; 89.2%). Among them, 84.3% had liver cirrhosis, 60.5% presented with elevated serum AFP level, and 80.2% had a single-tumor nodule at the time of resection (Table 1) . Clinical variables were similar in the three patient cohorts, with the exception of liver cirrhosis and tumor-node-metastasis stage. Fewer patients in cohort 2 had liver cirrhosis, and more patients in cohort 3 had early-stage tumors. Furthermore, in cohorts 2 and 3, 48.7% and 53.3% of the patients, respectively, had received "intention-to-cure" adjuvant IFN-a therapy, which improved overall survival. (15, 16, 21) As mentioned, we screened the expression of ISGs in HCC and found that the expression of IFIT family members, including IFIT1, IFIT2, IFIT3, and IFIT5, was significantly decreased in HCC tissues compared to their paired nontumor liver tissues (Fig. 1A,B) , suggesting a possible role of IFIT family members in HCC progression. We went further to analyze the expression and function of IFIT family members in HCC development, especially their correlation with response to adjuvant IFN-a therapy. In cohort 1, we examined the expression of IFIT1, IFIT2, IFIT3, and IFIT5 in HCC and the paired surrounding nontumor liver tissues of the 358 patients. Expression of IFIT1, IFIT2, and IFIT3 was significantly decreased in HCC tissues compared to their paired controls, while IFIT5 expression was less significant (Fig. 1C,D) . These results suggest that expression of IFIT1, IFIT2, and IFIT3 was decreased in HCC and that IFIT1, IFIT2, and IFIT3 might be involved in HCC progression.
PATIENTS WITH HIGH IFIT3 EXPRESSION IN HCC TISSUES RESPOND WELL TO IFN-a THERAPY
Because IFIT family members are typical ISGs, we evaluated whether the expression of IFITs in HCC was associated with response to IFN-a therapy in HCC patients. IFN-a therapy provided only limited P < 0.05 was adopted to indicate statistical significance. P values were calculated in SPSS 17.0 using the chi-squared test, except for age, which was calculated using one-way analysis of variance. Abbreviation: TNM, tumor-node-metastasis.
YANG, ZHOU, ET AL.
benefit on the overall survival of HCC patients in cohorts 2 and 3 ( Fig. 2A,B; Supporting Fig. S1A ). But after using the dichotomized value of IFIT family members' expression as cutoffs, we found that patients with high IFIT3 expression in HCC had significant improvement on overall survival after receiving adjuvant IFN-a therapy compared to those in the control group. In contrast, adjuvant IFN-a therapy had little effect on overall survival of the HCC patients with low IFIT3 expression in both cohorts. Dichotomized values of other IFIT members' expression levels, including those of IFIT1 and IFIT2, were not significantly correlated with IFN-a therapeutic response (Supporting Fig. S1B,C) . Cox proportional hazards regression analysis also confirmed the enhanced effect of adjuvant IFN-a therapy on overall survival of HCC patients in (Table  2 ). In both univariate and multivariate analyses, adjuvant IFN-a therapy correlated with significant improvement in survival of HCC patients with high IFIT3 expression. Interaction was observed between IFIT3 expression and IFN-a therapy with respect to the effect on survival (P 5 0.044 for interaction in cohort 2 and P 5 0.010 for interaction in cohort 3). In contrast, adjuvant IFN-a therapy had little effect on overall survival in patients in cohorts 2 and 3 with low IFIT3 expression (Supporting Table S1A ). We also found that IFIT3 expression in normal human liver tissues was similar to that in nontumor tissues (Supporting Fig. S1D ,E) and that IFIT3 protein was mainly expressed by hepatocytes in the liver (Supporting Fig. S1F ). Together, these data suggest that IFIT3 expression level in HCC tissues may be a potential independent predictor for IFN-a therapeutic response. It should be noted that the cohorts of HCC patients we analyzed were all Chinese patients with a high rate of chronic hepatitis B (Table 1 ). In HBV-related HCC patients in cohorts 2 and 3, we also determined that patients with high IFIT3 expression in HCC tissues had a significant improvement on overall survival after IFN-a therapy compared to those in the control group (Fig. 2C,D) . In HCCs derived from other diseases, the data are difficult to analyze statistically because of the limited number of patients. However, these data at least suggest that the evaluation of IFIT3 expression in HCC tissues may be helpful in the prediction of IFN-a response in HBV-related HCC patients.
IFIT3 ENHANCES ANTITUMOR EFFECTS OF IFN-a IN HCC BOTH IN VITRO AND IN VIVO
Next we investigated the role IFIT3 played in the response to IFN-a therapy in HCC experimental models both in vitro and in vivo. In human HCC cell inhibited by knockdown of IFIT3 or deficiency of IFIT3 ( Fig. 3C; Supporting Fig. S2B ). Knockdown or deficiency of IFIT3 also suppressed IFN-a-induced G 2 -M cell cycle arrest in HCC cell lines ( Fig. 3D ; Supporting Fig. S2C ). These results demonstrate that IFIT3 enhances response to IFN-a therapy of HCC in vitro.
In order to determine the role of IFIT3 in IFN-a response in vivo, we used the human HCC-bearing mouse model SMMC-LTNM. This model was created by transplanting histologically intact fresh human HCC tissues to nude mice to form subcutaneous transplant tumors, which were continuously maintained by subcutaneous passage. The SMMC-LTNM model closely mimics human HCC, and the tumor secretes AFP. (29) IFN-a therapy inhibited HCC growth of SMMC-LTNM in vivo, but the inhibitory effect mediated by IFN-a therapy was suppressed by intratumoral injection of cholesterol-conjugated IFIT3 siRNA, as examined by tumor size and serum AFP ( Fig. 3E; Supporting  Fig. S3A,B) . These results indicated that IFIT3 enhances response to IFN-a therapy of HCC in vivo.
Because the therapeutic effect of IFN-a is dependent on the induced expression of ISGs, four ISGs associated with the therapeutic effect of IFN-atumor necrosis factor-related apoptosis-inducing ligand, promyelocytic leukemia, X-linked inhibitor of apoptosis protein-associated factor 1, and 2 0 ,5 0 A-oligoadenylatesynthetase 1-were used to examine the effect of IFIT3 on IFN-a-induced ISG expression. (32, 33) Knockdown or deficiency of IFIT3 suppressed IFN-a-induced expression of these ISGs in HCC cell lines BEL-7402 and SMMC-7721 ( Fig.  4A; Supporting Fig. S4A ). Furthermore, in SMMC-LTNM, knockdown of IFIT3 in vivo inhibited IFNa-induced ISG expression (Fig. 4B) . Additionally, knockdown of IFIT3 attenuated ISG induction in the liver (Fig. 4C) . These data suggest that IFIT3 functionally promotes IFN-a-induced ISG expression in HCC, which may explain the association between IFIT3 expression and IFN-a therapeutic response both in vitro and in vivo.
IFIT3 STRENGTHENS IFN EFFECTOR SIGNALING BY PROMOTING STAT1-STAT2 DIMERIZATION AND NUCLEAR TRANSLOCATION
We further investigated the underlying mechanisms responsible for IFIT3-mediated promotion of response to IFN-a therapy. IFN-a treatment induces activation of the intracellular Janus kinase-STAT pathway, causing the phosphorylation and heterodimerization of STAT1 and STAT2; and then the heterodimer translocates into the nucleus and induces the expression of ISGs. (25, 34, 35) In HCC cells, knockdown of IFIT3 had little effect on the phosphorylation of STAT1 or STAT2 (Fig. 5A) . However, IFNa-induced nuclear translocation of STAT1 and STAT2 was significantly inhibited by knockdown or deficiency of IFIT3 ( Fig. 5A; Supporting Fig. S4B , C), suggesting that IFIT3 could promote the STAT1-STAT2 translocation induced by IFN-a treatment. Because the dimerization of STAT1 and STAT2 is important for their nuclear translocation, (25) we examined the interaction between STAT1, STAT2, and IFIT3. We found that IFIT3 could interact with STAT1 and STAT2 following IFN-a treatment using coimmunoprecipitation (Fig.  5B) ; however, IFN-a-induced interaction and heterodimerization between STAT1 and STAT2 were significantly inhibited by IFIT3 knockdown (Fig. 5C ). These data suggest that IFIT3 can interact with STAT1 and STAT2 and promote their interaction, heterodimerization, and subsequent nuclear translocation, thus enhancing IFN-a therapeutic response.
To identify the molecular mechanism of the interaction between STAT1, STAT2, and IFIT3, we constructed various fragments of STAT1, STAT2, and IFIT3. Through coimmunoprecipitation, we found that the N-terminal conserved domain of STAT1 and the DNA-binding Linker domain of STAT2 were responsible for the interaction between STAT1-IFIT3 and STAT2-IFIT3, respectively (Fig. 6A) . Also, the N-terminal domain of IFIT3 was responsible for STAT1-IFIT3 interaction, while the C-terminal domain of IFIT3 was responsible for STAT2-IFIT3 interaction (Fig. 6B,C) . Thus, IFIT3 associates with STAT1 through the N-terminal domain and associates with STAT2 through the C-terminal domain, which may contribute to the interaction and heterodimerization between STAT1 and STAT2. We conclude that IFIT3 strengthens IFN effector signaling by promoting STAT1-STAT2 dimerization and nuclear translocation.
Discussion
Besides surgical options, transcatheter arterial chemoembolization, radiofrequency ablation, sorafenib, and IFN-a therapy have shown clinical benefits to HCC patients. However, the advancing therapeutic options have been accepted to be relatively modest to date, and it remains difficult to generate a standard algorithmic approach to the control of this disease. (36) Preclinical data have indicated that several new approaches toward manipulating the immune response to HCC have therapeutic benefit in early-stage clinical trials, including cancer vaccine development, oncolytic viruses, and immune checkpoint inhibitors. (2) As for IFN-a therapy, a number of randomized controlled trials and previous meta-analyses have concluded that IFN-a provides a significant beneficial effect for surgery-treated HCC patients in terms of both overall and disease-free survival, with a pooled risk ratio of 0.65 and 0.86, respectively. (36) However, IFN-a therapy has not been widely accepted to treat HCC patients in clinical practice, possibly due to heterogeneous therapeutic responses and a variety of side effects. Recent studies indicate that IFN signaling plays an important role in integrating intrinsic mechanisms to profoundly influence treatment efficacy, by influencing immune determinants of therapeutic response. (37) Because a diversity of ISG functions contributes to dual functions of IFN signaling in the cancer environment, it would be helpful to understand the functions of important ISGs in the pathways. (22) Our work suggests that IFIT3 could be a biomarker to predict IFN-a therapeutic response.
For the expression of IFIT members in HCC, we found that IFIT1, IFIT2, and IFIT3 were all decreased in HCC samples but that only the IFIT3 expression level correlated with responses to adjuvant IFN-a therapy. This implies that IFIT1 and IFIT2 may be involved in HCC development and possibly have different mechanisms from that of IFIT3, which needs further study to fully elucidate. Our analysis showed that expression of IFIT1 and IFIT2 was not significantly correlated with responses to adjuvant IFN therapy, which might be due to limited patient samples and their weaker regulatory function of IFN effector signaling compared with that of IFIT3. Simultaneously, heterodimerization of STAT1-STAT2 plays pivotal roles in IFN effector signaling, and their interaction regulated by IFIT3 may be more important in IFN downstream signaling. Moreover, the phosphorylation of STAT1 and expression of IFIT1 are both down-regulated in hepatoma cells stimulated with IFN-b after histone deacetylase inhibitor treatment. (38) Thus, the mechanism of decreased expression of IFIT3 in HCC tissues may be correlated with deregulated histone deacetylation, which also needs to be further explored. IFIT family members have been identified as typical ISGs to commonly restrict viral replication during infection through alteration of protein synthesis, IFN production, and direct binding to viral RNA with 5 0 ppp modification. (39) (40) (41) IFIT3 interacts with TANKbinding kinase-1 and mitochondrial antiviral signaling protein in order to promote IFN production. (42) In this study, we found that IFIT3 also promoted IFN-a effector signaling through enhanced STAT1-STAT2 dimerization and nuclear translocation, and high IFIT3 expression in HCC predicted better response of HCC patients to adjuvant IFN-a therapy. In the interaction of IFIT3 between STAT1 and STAT2, we find that the N-terminal conserved domain of STAT1 and the N-terminal domain of IFIT3 were responsible for STAT1-IFIT3 interaction and that the DNA-binding Linker domain of STAT2 and the C-terminal domain of IFIT3 were responsible for STAT2-IFIT3 interaction. Together with the data that IFIT3 promotes STAT1 and STAT2 dimerization, these data strongly suggest that IFIT3, STAT1, and STAT2 can form a complex to initiate downstream activation of ISG transcription. The details of the formation of this complex, especially the structural data and various posttranslational modifications of these molecules, still warrant further investigation to elucidate their interaction.
As ISGs, IFIT family members are involved in antiviral functions upon viral infection. (42) (43) (44) In HBV infection and HBV-related HCC, it is possible that IFIT3 might influence the replication of HBV and then modulate the responses of HCC patients to IFNa treatment. However, for IFIT3 and HBV replication, we performed a Pearson correlation coefficient assay of HBV DNA copy before surgery and hepatic IFIT3 expression in cohort 2 and found that HBV DNA copy is poorly correlated with hepatic IFIT3 expression (data not shown). We also transfected 1.3-mer HBV genome into HCC SMMC-7721 and BEL-7402 cells and found that IFIT3 expression was not influenced by HBV replication (data not shown). Furthermore, in HepG2.2.15 (HBV-transformed) cell line, knockdown of IFIT3 did not influence HBV replication (data not shown). Thus, HBV replication and hepatic IFIT3 expression may be poorly correlated. As HBV-related HCC is extremely prevalent in China, we focused on HBV-related HCC in this study. At least, evaluation of IFIT3 expression in HCC tissues is suggested to be helpful in the prediction of IFN-a response in HBV-related HCC patients.
In summary, our findings reveal that IFIT3 expression in HCC tissues is correlated with responses to adjuvant IFN-a therapy in patients. IFIT3 can promote IFN-a effector signaling by enhancing STAT1-STAT2 heterodimerization and nuclear translocation. Our data may have considerable potential in future decision-making in the treatment of HCC patients by IFN-a.
